Affibody

Affibody is a clinical-stage biotech pioneering a new generation of targeted radioligand therapies (RLTs) for oncology using its proprietary Affibody® molecule platform. The company's strategy focuses on targets and cancer indications with high unmet need where its small, engineered protein scaffolds offer potential competitive advantages in tumor penetration and clearance. Beyond its core oncology pipeline, Affibody generates value through partnership programs in immunology and has established key collaborations for radiopharmaceutical supply and development. With a strong scientific foundation, a deep pipeline, and a seasoned team, Affibody is positioned as a notable player in the expanding radiopharmaceutical therapeutics field.

Proprietary Affibody® platform: small (6 kDa), engineered protein scaffolds used to create precision-targeting molecules for radioligand therapies (RLTs). Offers advantages in tissue penetration, rapid clearance, and stability.

Affibody competes in the radiopharmaceutical space with large players like Novartis (Pluvicto, Lutathera) and a growing number of biotechs (e.g., RayzeBio, Fusion Pharmaceuticals). Its competitive edge is based on the small size and pharmacokinetic profile of its Affibody molecules, which may offer advantages over antibody-based RLTs. In immunology, izokibep competes with established IL-17 inhibitors like Cosentyx.